SB 1199 requires health care service plans regulated by the Department of Managed Health Care and health insurers regulated by the Department of Insurance to count any amount paid by an enrollee or paid on the enrollee's behalf for a prescription drug toward the enrollee’s in‑network deductible and annual limitation on cost sharing. The bill explicitly includes manufacturer direct support when that support is permitted under California’s Division 114 drug‑pricing provisions.
The change narrows a common industry practice of excluding third‑party payments (for example, coupons or manufacturer assistance) from deductible and out‑of‑pocket calculations. For California‑regulated, nongrandfathered plans that cover essential health benefits, the measure lowers the barrier to reaching plan maximums but raises immediate operational and enforcement questions for insurers, plans, PBMs, and pharmacies.
At a Glance
What It Does
The bill directs health care service plans and health insurers to count any amount the enrollee pays or that is paid on the enrollee’s behalf for a drug toward the enrollee’s annual limitation on cost sharing and applicable in‑network deductible. It cross‑references Division 114 to limit the counting of manufacturer support to circumstances where that support is permitted.
Who It Affects
Applies to nongrandfathered California health care service plan contracts and health insurance policies that are subject to state essential health benefits statutes; it does not apply to grandfathered plans, many limited‑benefit policies, Medicare supplement, or self‑insured (ERISA) employer plans outside state regulation.
Why It Matters
This changes how point‑of‑sale and post‑pay assistance alter patient liability and plan accounting. Compliance teams, PBMs, pharmacies, and state regulators will need to update adjudication, reimbursement, and reporting practices; consumer advocates view it as a vehicle to reduce patients’ immediate out‑of‑pocket burdens.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB 1199 creates a rule for California‑regulated health plans and insurers that forces them to treat payments toward prescription drugs — whether paid by the enrollee, by a manufacturer on the enrollee’s behalf, or by another third party — as money applied to the enrollee’s in‑network deductible and to the plan’s annual limit on cost sharing. The bill places this rule in both the Health and Safety Code (for Knox‑Keene plans) and the Insurance Code (for insurers) and defines cost sharing by reference to federal ACA regulations (45 C.F.R. §155.20).
The statute makes clear that manufacturer direct support is included only when that support is permitted under Division 114 of the Health and Safety Code, and it preserves the division’s limitations (see Sections 132000 and 132002) rather than overriding them. The bill enumerates several exclusions: grandfathered plans, specialized plans that do not provide essential health benefits, Medicare supplement plans, and limited‑benefit products such as accident‑only or hospital indemnity policies are outside its scope.Enforcement differs depending on the regulated entity.
For insurers, the Insurance Commissioner gains explicit authority to assess administrative penalties up to $5,000 per violation, and up to $10,000 per violation if the violation is found to be willful, after notice and a hearing under government administrative procedure statutes. For Knox‑Keene plans, a willful violation of the Health and Safety Code provision is a willful violation of the Knox‑Keene Act, which can carry criminal exposure under existing law; the bill treats those criminalization consequences as creating a state‑mandated local program.Practically, the bill forces operational changes: adjudication systems must accept and attribute third‑party payments to member liabilities; PBMs and pharmacies will need processes to flag and reconcile manufacturer assistance at point‑of‑sale or later; and regulators will need to issue guidance on what documentation suffices to prove that a payment was made “on behalf of” a patient.
The statute does not create an explicit timeline for implementation or detailed reconciliation rules, leaving significant administrative choices to regulators and regulated entities.
The Five Things You Need to Know
The bill requires California‑regulated health plans and insurers to count any amount paid by the enrollee or paid on the enrollee’s behalf for a prescription drug toward the enrollee’s in‑network deductible and annual limitation on cost sharing.
Manufacturer direct support is included only when that assistance is permitted under Division 114 of the Health and Safety Code; the bill explicitly preserves Division 114’s limits (Sections 132000 and 132002).
Coverage scope: the rule applies to nongrandfathered plans and policies subject to California essential health benefit statutes and excludes grandfathered plans, Medicare supplement, accident‑only, specified disease, and hospital indemnity products.
For health insurers, the Insurance Commissioner may assess administrative penalties up to $5,000 per violation and up to $10,000 per violation if the violation was willful, after notice and opportunity for a hearing.
For health care service plans subject to Knox‑Keene, a willful violation of the new provision constitutes a willful violation of the Act and therefore can trigger criminal penalties under existing law; the bill treats those consequences as a state‑mandated local program.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Count third‑party and patient drug payments toward plan cost sharing
This provision directs Knox‑Keene‑regulated health care service plans to count any payment by the enrollee or paid on the enrollee’s behalf for a drug toward the enrollee’s annual cost‑sharing limit and applicable in‑network deductible. It adopts federal terminology for cost sharing and ties the counting rule to essential health benefits, which narrows the rule to benefits subject to ACA‑style protections. The practical implication is that plans must adjust claims adjudication and member accounting so that qualifying third‑party contributions reduce remaining member liability.
Applicability, exclusions, and reference to Division 114
Subsections specify that the rule applies only to nongrandfathered contracts subject to Section 1367.006 and excludes several limited‑benefit and grandfathered products. The text also ties manufacturer assistance to Division 114, meaning plans cannot count manufacturer support in circumstances where Division 114 itself prohibits or limits that support. This cross‑reference creates an implementation dependency: plans and regulators will need to reconcile Division 114’s eligibility and limits before applying the counting rule.
Equivalent counting rule for regulated health insurers plus enforcement
This section mirrors the Health and Safety Code rule for insurers and includes identical scope and Division 114 cross‑references. It adds an explicit enforcement mechanism: the Insurance Commissioner may pursue administrative enforcement under California administrative procedure chapters and assess penalties up to $5,000 per violation or $10,000 per violation if willful. That creates a civil administrative deterrent specifically tailored to insurers, separate from criminal exposure for Knox‑Keene plans.
Fiscal note: no state reimbursement required for local costs
The bill declares that no reimbursement is required under Article XIII B because any local costs stem from criminal‑law changes (willful violations) and fall within existing exceptions. This is a standard fiscal clause but signals that the Legislature considers criminal sanction exposure for plan willful violations as the primary local fiscal impact.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with high prescription drug costs who use manufacturer assistance: they reach deductibles and out‑of‑pocket maximums faster because third‑party payments will reduce their remaining liability.
- Consumers using copay assistance at point‑of‑sale: immediate relief from coinsurance or copayment burdens when the assistance is applied and counted toward plan limits.
- Consumer advocates and patient support organizations: the bill creates a clear statutory right to have qualifying payments credited, simplifying legal and advocacy remedies when plans refuse to count assistance.
- Pharmacies serving patients who rely on assistance programs: clearer rules can reduce disputes at point‑of‑sale about whether a payment reduces a patient’s deductible or OOP maximum.
Who Bears the Cost
- Health insurers and managed care plans regulated in California: they must change adjudication systems, create verification procedures for third‑party payments, and bear potential penalties for noncompliance.
- Pharmacy benefit managers (PBMs): PBMs will face heavier operational burdens reconciling manufacturer programs with member liability accounting and may need contract changes with plans and pharmacies.
- State regulators (DMHC and Department of Insurance): regulators must issue implementation guidance, adjudicate disputes, and enforce penalties, increasing regulatory workload.
- Employers purchasing fully insured plans in California: while not directly fined, employers could see premium impacts if insurers adjust pricing to reflect changes in how assistance is counted and utilized.
Key Issues
The Core Tension
SB 1199 pits two legitimate objectives against each other: reducing immediate financial burden for patients by counting third‑party payments toward deductibles and out‑of‑pocket maximums, versus the administrative, anti‑fraud, and cost‑allocation burdens that come with recognizing and reconciling those payments. The bill solves the consumer accounting problem but transfers complexity to adjudicators, regulators, and payment intermediaries without prescribing the detailed reconciliation or verification rules those actors need.
The statute is deceptively simple language that leaves a large share of implementation detail unresolved. It requires plans and insurers to count third‑party payments, but it does not define operational mechanics: who certifies that a payment was made “on behalf of” an enrollee, whether point‑of‑sale coupon use and later rebate reconciliation both qualify, or how to handle retroactive payments and appeals.
Those choices affect cash flow for pharmacies, timing of member liability relief, and fraud controls.
Another unresolved area is the scope of "on behalf of" payments beyond manufacturer support. Because the text does not expressly exclude charitable assistance or payments from foundations, insurers may contest whether certain third‑party programs qualify.
The bill's reliance on Division 114 limits manufacturer support but does not address patient assistance foundations or independent charities—leaving room for disputed interpretations and litigation. Finally, the mismatch in enforcement paths creates an asymmetry: insurers face administrative fines while Knox‑Keene plans may face criminal exposure for willful violations, producing different incentives and possible forum shopping for regulatory complaints.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.